Pharmacy News

MSD’s Keytruda scores EU approval in certain oesophageal cancer patients

MSD’s immunotherapy Keytruda has received approval from the European Commission (EC) in combination with chemotherapy as a first line treatment for certain oesophageal cancer patients.

The EC has authorised Keytruda (pembrolizumab) in combination with platinum- or fluoropyrimidine-based chemotherapy for the initial treatment of patients with locally advanced unresectable or metastatic oesophageal cancer or HER2-negative gastroesophageal junction (GEJ) cancer in adults whose tumours express PD-L1.

The approval is based on data from the Phase III KEYNOTE-590 trial, which enrolled 749 patients with locally advanced unresectable or metastatic oesophageal or GEJ cancer, who were not eligible for surgery or definitive chemoradiation.

In this trial, Keytruda plus 5-fluorouracil (5-FU) and cisplatin reduced the risk of death by 27% and reduced the risk of disease progression or death by 35% compared with 5-FU and cisplatin alone.

A pre-specified analysis of patients whose tumours expressed PD-L1 showed Keytruda plus 5-FU and cisplatin reduced the risk of death by 38% and reduced the risk of disease progression or death by 49% versus chemotherapy alone.

In addition to the overall survival (OS) and progression-free survival (PFS) data, Keytruda plus 5-FU and cisplatin-treated patients demonstrated an objective response rate (ORR) of 51.1%, with a complete response (CR) rate of 5.9% and a partial response (PR) rate of 45.2%.

Again, this was an improvement on 5-FU and cisplatin alone, with patients in this group demonstrating ORR of 26.9%, with a CR rate of 2.5% and a PR rate of 24.4%.

“Keytruda plus chemotherapy is the first anti-PD1 therapy approved in Europe in this first-line setting, allowing these patients to be treated with immunotherapy earlier in the course of their treatment,” said Scot Ebbinghaus, vice president, clinical research, Merck Research Laboratories.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button

Ad Block Detected

Welcome to Mediexpose, Please support our journalism by allowing ads. With support from readers like you, we can continue to deliver the best. You can support us free by simply allowing ads.